Patent · US Active

Anti-FGFR2 antibodies

US8481688B2 · kind B2 · utility

7Cited by

7References

7Claims

0Family size

Assignee

AVEO Pharmaceuticals, Inc. · US

Inventors

Zhigang Weng · Cambridge, US
William M. Winston, Jr. · Marlborough, US
Ailin Bai · Newton, US
Kristan Meetze · Lexington, US
Solly Weiler · Newton, US
Ting Chen · Austin, US
Jeno Gyuris · Lincoln, US

Key dates

Filing date	May 11, 2011
Grant date	Jul 9, 2013
Priority date	—
Expiry date	Aug 5, 2031

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/92
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Monoclonal antibodies that bind and inhibit biological activities of human FGFR2 are disclosed. The antibodies can be used to treat cell proliferative diseases and disorders, including certain forms of cancer, associated with activation or overexpression of FGFR2.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.